Explore

Reuters Reuters
Novo Nordisk shares rise as Hims abandons $49 weight-loss pill

Novo Nordisk shares rise as Hims abandons $49 weight-loss pill

COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of a $49 weight-loss pill over the weekend, following legal threats from Novo and the U.S. Food and Drug Administration.
Reuters Reuters
Weight-loss drugs to compete on biggest stage with Super Bowl ads

Weight-loss drugs to compete on biggest stage with Super Bowl ads

By Amina Niasse NEW YORK, Feb 7 (Reuters) - Companies looking to sell weight-loss drugs directly to consumers, including Novo Nordisk's Wegovy, will shell out millions of dollars for celebrity-filled ads during Sunday's Super Bowl with its promise of one of the year's largest global audiences.
Rapid Read Rapid Read
India Prepares to Produce Cheaper Generic Versions of Ozempic as Patent Expires

India Prepares to Produce Cheaper Generic Versions of Ozempic as Patent Expires

India is gearing up to produce generic versions of semaglutide, the active ingredient in Novo Nordisk's Ozempic, as the patent is set to expire in March. Indian pharmaceutical companies, including Dr. Reddy's Laboratories and Cipla, are preparing to manufacture these weight-loss drugs, potentially reducing prices significantly. Analysts predict a price war in India, with costs dropping by up to 90%. This development could position India as a major supplier of affordable weight-loss medications, similar to its role in the global supply of HIV drugs.
Trendline Trendline
FDA to Restrict GLP-1 Ingredients in Non-Approved Compounded Drugs, Impacting Hims

FDA to Restrict GLP-1 Ingredients in Non-Approved Compounded Drugs, Impacting Hims

FDA to Restrict GLP-1 Ingredients in Non-Approved Compounded Drugs, Impacting Hims
Rapid Read Rapid Read
India's Generic Drug Production Could Lower Global Weight-Loss Drug Costs

India's Generic Drug Production Could Lower Global Weight-Loss Drug Costs

India is poised to significantly impact the global market for weight-loss drugs as the patent for semaglutide, a key ingredient in Novo Nordisk's Ozempic, is set to expire. Indian pharmaceutical companies, including Dr. Reddy’s Laboratories and Cipla, are preparing to produce generic versions of semaglutide, potentially reducing costs by up to 90%. This development mirrors India's past role in making HIV drugs more affordable and accessible. The move is expected to transform India into a major supplier of affordable weight-loss medications, addressing the country's growing obesity and diabetes challenges.
AP News AP News
Spiritual ties of ousted Venezuelan President Maduro and successor include guru Sathya Sai Baba

Spiritual ties of ousted Venezuelan President Maduro and successor include guru Sathya Sai Baba

Venezuela’s former President Nicolás Maduro and the country’s acting President Delcy Rodríguez were both raised Catholic in an overwhelmingly Christian country
AP News AP News
Amazon's shares fall after announcing surge in capital spending but posts strong 4Q holiday sales

Amazon's shares fall after announcing surge in capital spending but posts strong 4Q holiday sales

Amazon sales surged 14% during the fourth quarter, helped by strong holiday spending and a better-than-expected growth in its prominent cloud computing unit
AP News AP News
Wall Street bounces back as tech stocks recover some losses and bitcoin stops plunging

Wall Street bounces back as tech stocks recover some losses and bitcoin stops plunging

U.S. stocks are bouncing back from big swings that pummeled them this week
Reuters Reuters
Novo Nordisk shares rebound as FDA targets illegal drug copies

Novo Nordisk shares rebound as FDA targets illegal drug copies

By Jacob Gronholt-Pedersen COPENHAGEN, Feb 6 (Reuters) - Shares in Danish drugmaker Novo Nordisk gained 5.2% on Friday, recovering some of the previous two sessions' steep losses, after the U.S. Food and Drug Administration (FDA) pledged to address mass-marketing of unapproved drugs.
Trendline Trendline
Hims Hers Disrupts Weight-Loss Drug Market with Affordable Alternative

Hims Hers Disrupts Weight-Loss Drug Market with Affordable Alternative

Hims Hers Disrupts Weight-Loss Drug Market with Affordable Alternative
Trendline Trendline
Novo Nordisk to Pursue Legal Action Against Hims Hers Over Wegovy Pill Copy

Novo Nordisk to Pursue Legal Action Against Hims Hers Over Wegovy Pill Copy

Novo Nordisk to Pursue Legal Action Against Hims Hers Over Wegovy Pill Copy
Rapid Read Rapid Read
FDA Targets Compounded Weight-Loss Drugs, Impacting Hims Hers

FDA Targets Compounded Weight-Loss Drugs, Impacting Hims Hers

The U.S. Food and Drug Administration (FDA) has announced plans to restrict the use of GLP-1 ingredients in non-approved compounded weight-loss drugs, affecting companies like Hims & Hers. The FDA's action comes amid concerns over the quality and safety of these drugs, which are marketed as cheaper alternatives to authorized treatments. Hims & Hers recently introduced a $49 weight-loss pill, significantly undercutting the price of Novo Nordisk's Wegovy pill. The FDA's enforcement actions could include warning letters, court injunctions, or product seizures, with potential involvement from the Department of Justice.